Proteomics

Dataset Information

0

Proteomic analysis of melanoma resistant cells transfected with siRNA targeting DDR2 or treated with DDR2 inhibitor or Dasatinib


ABSTRACT: Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In 70% of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Melanoma

SUBMITTER: Dupuy Jean-William  

LAB HEAD: Frédéric Saltel

PROVIDER: PXD028292 | Pride | 2023-05-02

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
F008358.dat Other
F008360.dat Other
F008364.dat Other
F008365.dat Other
F008368.dat Other
Items per page:
1 - 5 of 39
altmetric image

Publications


Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low,  ...[more]

Similar Datasets

2021-09-13 | PXD004145 | Pride
2023-09-25 | PXD037252 | Pride
2023-11-01 | PXD039470 | Pride
2023-09-25 | PXD037248 | Pride
2023-08-24 | GSE221241 | GEO
2023-05-31 | PXD029834 | Pride
2018-03-14 | PXD005091 | Pride
2023-09-08 | PXD038822 | Pride
2024-07-08 | PXD043841 | Pride
2020-06-28 | PXD017215 | Pride